Choroid plexus tumors are uncommon neoplasms derived
|
|
- Rudolf Hart
- 3 years ago
- Views:
From this document you will learn the answers to the following questions:
What type of cancer is Choroid plexus carcinoma?
Is the choroid plexus carcinoma usually found in adults?
What is the mitotic activity in choroid plexus carcinoma?
Transcription
1 Resident Short Reviews Choroid Plexus Carcinoma Purva Gopal, MD; John R. Parker, MD; Robert Debski, MD; Joseph C. Parker, Jr, MD Choroid plexus carcinoma is an uncommon neoplasm of the central nervous system most commonly found in the pediatric population. It is associated with a dismal prognosis, especially if incompletely resected. Accurate histopathologic diagnosis is imperative, and this neoplasm should always be included in the differential diagnosis of a papillary intraventricular tumor. Histopathologic features include blurring of papillary architecture, layers of neoplastic choroid plexus epithelial cells with pleomorphic nuclei, increased nuclear-to-cytoplasmic ratio, increased mitotic activity, areas of necrosis, and brain invasion. Current accepted treatment is gross total surgical resection of the tumor as the goal. Use of adjuvant chemotherapy is controversial at this time; however, it is considered in some cases. (Arch Pathol Lab Med. 2008;132: ) Choroid plexus tumors are uncommon neoplasms derived from choroid plexus epithelium and characterized by papillary and intraventricular growth. Within this family of tumors, there are benign and malignant variants, typically classified as choroid plexus papilloma (CPP) and choroid plexus carcinoma (CPC), respectively. Choroid plexus tumors account for approximately 0.4% to 0.6% of all brain tumors. 1 Within the pediatric population, however, these neoplasms are more common, representing approximately 1% to 4% of all childhood brain tumors, with 10% to 20% occurring during the first year of life. 1 Although reported in adults, 80% of CPCs occur in the pediatric population, and 20% to 40% of all choroid plexus tumors in children are CPCs. 1 Choroid plexus carcinoma is a highly aggressive malignant tumor (World Health Organization [WHO] grade III) which must be distinguished from CPP (WHO grade I). Distinction between these entities is imperative but can be challenging, and it is generally based on increased necrosis, mitotic activity, and change in growth pattern. 2 According to some authors, 3,4 histologic features may have Accepted for publication January 10, From the Department of Pathology and Laboratory Medicine (Dr Gopal) and the Department of Pathology and Laboratory Medicine, Division of Neuropathology (Drs J. R. Parker and J. C. Parker, Jr), University of Louisville, Louisville, Ky; and the Department of Pathology and Laboratory Medicine, Kosair Children s Hospital, Louisville, Ky (Dr Debski). The authors have no relevant financial interest in the products or companies described in this article. Reprints: Joseph C. Parker, Jr, MD, Department of Pathology and Laboratory Medicine, University of Louisville Hospital, 530 S Jackson St, Room COF19, Louisville, KY ( jcpark01@gwise. louisville.edu). no correlation with biologic behavior in that both CPPs and CPCs have been associated with metastatic disease. 5 The atypical choroid plexus papilloma has been described as a tumor with a few histologic features of malignancy, but diagnostic criteria for this classification are vague. Current treatment strategy consists of gross total surgical resection for both CPP and CPC, with controversial use of adjuvant chemotherapy and radiotherapy for patients with CPC. 3 Complete resection is difficult due to the high risk of intraoperative hemorrhage; however, review of the literature supports complete surgical resection as the major prognostic factor for patients with CPC. 4 CLINICAL FEATURES Choroid plexus carcinoma is an uncommon, aggressive, malignant, central nervous system neoplasm that typically occurs in children and presents with the signs and symptoms of cerebrospinal fluid obstruction. Within the pediatric population, the median age is approximately 26 to 32 months. 1 Choroid plexus carcinomas are believed to arise from the choroid plexus epithelium. In general, they occur as follows: 50% lateral ventricles, 40% fourth ventricle, 5% third ventricle, and 5% multiple ventricular involvement. 1,6 Although infrequent, CPCs can occur in the cerebellopontine angle near the foramina of Lushka, and extremely rare cases may present as a suprasellar and/or intraparenchymal mass. 6 8 Choroid plexus carcinoma has been associated with obstruction of the cerebrospinal fluid pathways and, potentially, overproduction of cerebrospinal fluid, leading to hydrocephalus and increased intracranial pressure. 6 An infant may present with hydrocephalus manifesting with increased head circumference, and signs and symptoms of increased intracranial pressure, including delayed development, bulging fontanelles, separated sutures, strabismus, or vomiting. An older child or adult can present with features of increased intracranial pressure, including vomiting, headache, neurologic deficits, seizures, lethargy, visual, and/or behavioral changes. NEUROIMAGING Studies generally include computed tomography and/ or magnetic resonance imaging. These radiographic studies typically demonstrate a large, hyperdense, contrast-enhancing, intraventricular mass (Figure 1). The tumor is usually associated with hydrocephalus and may contain focal calcification and hemorrhage. The vascular nature of the neoplasm can be appreciated with multiple flow voids. 6 Choroid plexus carcinoma may have metastases 1350 Arch Pathol Lab Med Vol 132, August 2008 Choroid Plexus Carcinoma Gopal et al
2 Figure 1. Magnetic resonance image demonstrating a large mass within the right lateral ventricle extending into the basal ganglia and laterally into the right temporoparietal region and occipital lobe in a 5-year-old boy with choroid plexus carcinoma. Figure 2. Choroid plexus carcinoma with nuclear pleomorphism and high vascularity (hematoxylin-eosin, original magnification 400). Figure 3. Choroid plexus carcinoma with areas of necrosis (hematoxylin-eosin, original magnification 100). Figure 4. Solid sheet of choroid plexus carcinoma invading adjacent brain parenchyma (hematoxylin-eosin, original magnification 100). Figure 5. Markedly increased MIB-1 nuclear labeling in choroid plexus carcinoma (original magnification 400). Figure 6. Positive cytokeratin (CAM 5.2) staining in choroid plexus carcinoma (original magnification 100). Arch Pathol Lab Med Vol 132, August 2008 Choroid Plexus Carcinoma Gopal et al 1351
3 along the cerebrospinal fluid pathways, so imaging the entire neuraxis is important. GROSS PATHOLOGY Choroid plexus carcinomas typically have a friable papillary or cauliflower-like appearance. Intraoperatively, CPCs may be loosely or densely adherent to the ventricular wall and minimally or widely invade the adjacent brain parenchyma. On sectioning, the tumors display solid areas intermixed with necrotic and hemorrhagic foci. Unlike CPCs, CPPs are usually well delineated from the underlying brain parenchyma and lack necrosis. 1,6 HISTOPATHOLOGY/ DIAGNOSIS Choroid plexus papilloma is characterized as a WHO grade I neoplasm, and it is histologically described as a benign tumor with a papillary configuration consisting of delicate fibrovascular cores lined by a single layer of cuboidal to columnar epithelium. The epithelial cytoplasm is abundant and eosinophilic, and the tumor nuclei are basal, monomorphic, and round to oval. The difference between CPP and normal choroid plexus resides in the crowding and elongation of cells in the papilloma. There is no invasion or necrosis, and mitotic activity should be rare. When a CPP has some limited malignant features, the diagnosis atypical choroid plexus papilloma is appropriate; however, distinctive criteria for diagnosis are not established. 1 A 2006 study by Jeibmann et al 9 examined a series of 164 choroid plexus tumors for the presence of atypical features and correlated these features with prognosis in an effort to create criteria for the diagnosis of atypical CPP. They showed that mitotic activity is the only feature that impacted the probability of recurrence in patients diagnosed with CPP. The group proposed that a mitotic count greater than or equal to 2 per 10 high-power fields could define a choroid plexus tumor as atypical, and the same study suggested that if at least two of the following histologic features are seen, including increased cellularity, nuclear pleomorphism, solid growth pattern, and/or necrosis, a diagnosis of atypical CPP would be warranted. 9 Using these criteria, the study examined a series of 124 previously diagnosed CPPs, and 15% of these were atypical CPPs. 9 Malignant evolution of a CPP which recurred as CPC has been reported in two patients, 3 but documented transition from benign to malignant histology is extremely rare. 10 In comparison with the papilloma, the diagnosis of CPC is rendered in the setting of increased cell density, increased mitotic figures (usually greater than 5 per 10 highpower fields), nuclear pleomorphism (Figure 2), and necrosis (Figure 3). Diffuse invasion of the adjacent brain parenchyma is often present (Figure 4). While distinct papillary configuration is a hallmark of low-grade CPP, in CPC the papillary features are blurred or can be lost in the sheets of epithelial tumor cells, and this ill-defined growth pattern can make diagnosis challenging. 3,10 Proliferation indices, such as Ki-67/MIB-1 (Figure 5) can be useful in the diagnosis of CPC, with reported mean nuclear labeling rates of 1.9% for CPP and 13.8% in CPC. Choroid plexus carcinoma is classified as a WHO grade III tumor. 1 DIFFERENTIAL DIAGNOSIS An expansive differential diagnosis can be created in the clinical setting of an intraventricular papillary tumor. Within the choroid plexus, in addition to CPC and CPP, another consideration is villous hypertrophy of the choroid plexus, which is a benign proliferation causing enlargement of the choroid plexus in the lateral ventricles. Microscopically, these lesions have normal choroid plexus histology 1 and can also be distinguished from a neoplastic lesion using proliferation markers. 11 Ependymoma, particularly the papillary variant, is an additional consideration; however, characteristic cytologic and morphologic features on histologic examination, especially in a well-differentiated ependymoma, should be present. These features include monomorphic cuboidal cells with a flattened surface, 6 micronucleoli, stippled chromatin, ependymal rosettes, and the presence of perivascular pseudorosettes consisting of tapered cell processes oriented toward a central blood vessel. 12 Papillary meningioma, a rare highgrade (WHO grade III) variant of meningioma, can arise in the choroid plexus, especially in patients in the pediatric age group. 12,13 This tumor is described histologically as having a pseudopapillary or perivascular pattern in part of the tumor, which makes this meningioma a WHO grade III neoplasm. In infants, some embryonal-type (primitive neuroectodermal) tumors can occur in the same area. Of these, specific attention should be given to atypical teratoid/rhabdoid tumor (AT/RT), due to its aggressive nature. Histologically, AT/RT usually has groups of rhabdoid cells with eccentric, pleomorphic nuclei, and abundant eosinophilic cytoplasm. These tumors are high grade, with increased mitoses and necrosis. Atypical teratoid/rhabdoid tumor can be somewhat challenging to distinguish from CPCs that are poorly differentiated with foci of epithelial differentiation. Immunohistochemical staining can be useful in distinguishing between the two tumors, and it will be discussed in further detail below. Finally, metastatic neoplasms to the choroid plexus, especially in the adult population, are possible. The reported incidence of solitary metastases to the choroid plexus with no evidence of tumor in the brain parenchyma is rare, accounting for 0.14% of all cerebral metastases, the most common in adults being renal cell carcinoma. 14,15 IMMUNOHISTOCHEMISTRY Choroid plexus carcinomas typically stain positive for cytokeratins, and display variable expression of vimentin, S100, transthyretin, and glial fibrillary acidic protein (GFAP) (Figure 6). Positivity for S100 and transthyretin is typically less than that seen in CPP. Choroid plexus carcinomas stain positive for GFAP in approximately 20% of tumors, and they can express carcinoembryonic antigen. 1,10 Choroid plexus carcinomas are typically negative for epithelial membrane antigen. The staining characteristics of CPC are somewhat inconsistent in that the commonly used markers lack specificity Hasselblatt et al 2 recently described a microarray-based approach to identify new diagnostic markers for CPC. Antibodies directed against stanniocalcin 1, a glycoprotein found in choroid plexus, and Kir 7.1, a choroid plexus apical epithelial protein thought to be involved in transepithelial potassium transport, were found to be specifically expressed in CPC and CPP, and could further assist in the diagnosis of these neoplasms. 2 Furthermore, in 2006, Judkins et al 19 developed an immunohistochemical stain using the BAF47 clone of INI1 antigen. INI1 is a tumor suppressor gene that can be deleted and/or mutated in AT/RT. The group compared INI1 staining in CPC and AT/RT and found that most 1352 Arch Pathol Lab Med Vol 132, August 2008 Choroid Plexus Carcinoma Gopal et al
4 Immunohistochemical Staining of Tumors in Differential Diagnosis of Choroid Plexus Carcinoma (CPC)* CAM 5.2 Transthyretin GFAP Epithelial Membrane Antigen INI1 Kir 7.1 Stanniocalcin 1 CPC / / Papillary ependymoma NA / Papillary meningioma NA NA NA NA Atypical teratoid/rhabdoid tumor / NA / * GFAP indicates glial fibrillary acidic protein;, present;, absent; and NA, not applicable. CPCs (21/28) stained positively for INI1, whereas the majority of AT/RTs did not stain. This immunostain could potentially assist in distinguishing between a poorly differentiated CPC and an AT/RT with extensive epithelial differentiation (Table). GENETICS Choroid plexus carcinoma has been described in association with Li-Fraumeni syndrome in families that carry TP53 germline mutations. The TP53 gene is located on chromosome 17p13.1 and encodes the tumor suppressor protein p53. A mutation of this gene causes loss of p53 function and prolongs the half-life of this protein. Appropriately, immunohistochemical staining for p53 can be increased in this setting. 20 According to a 2002 study by Carlotti et al, 21 positive nuclear staining for p53 was found in 10 of 11 CPCs, whereas only 1 of 12 CPPs stained positively. Also in 2002, 5 new families of pediatric patients with CPC were identified with TP53 mutations. This strengthens the previous belief that CPC could be used as an indicator of a germline TP53 mutation, especially in the setting of a family history of cancer. 22 Somatic TP53 mutations and spontaneous germline mutations have also been identified in some CPCs. 23 The presence of this genetic defect is believed to have important implications in the prevention and treatment of cancers in affected families. 21 Comparative genomic hybridization has demonstrated the following common chromosomal additions and deletions in CPCs: 12p, 12q, and 20p (60%); 1, 4q, and 20q (53%); 4p (47%); 8q and 14q (40%); 7q, 9p, and 21 (33%); 22q (73%); 5q (40%); and 5p and 18q (33%). 22,23 A study by Rickert et al 24 also examined the behavior of CPCs with certain chromosomal additions and deletions and concluded that tumors with a gain of 9p and loss of 10q were associated with significantly longer survival. TREATMENT/PROGNOSIS Choroid plexus carcinomas usually grow rapidly and have a 5-year survival rate of approximately 40%. Two thirds of these tumors disseminate throughout the cerebrospinal fluid pathway, and malignant cells may be present in cerebrospinal fluid prior to resection. Systemic metastases may be seen in patients with longer survival. 10 There is currently no established protocol for the treatment of CPC; however, complete resection of the tumor is the primary goal. Gross total resection allows for the best chance of survival and improves the overall prognosis, 4,25 but complete resection is achieved in only 40% to 50% of children with CPC. 26,27 The prognosis of CPC is grave if not totally resected. Complete resection of this neoplasm is associated with high morbidity due to such factors as patient age, widespread tumor dissemination, and tumor vascularity, which puts patients at increased risk for intraoperative hemorrhage. The use of neoadjuvant chemotherapy to reduce tumor vascularity prior to surgery has been reported 28 ; however, this has not been accepted as a standard approach. Adjuvant chemotherapy after surgery remains controversial. 29 Some studies have demonstrated a decrease in tumor recurrence with adjuvant chemotherapy, whereas others have not shown any benefit. 30 Although some studies have demonstrated the benefit of postsurgical radiation therapy, radiation is generally avoided in the pediatric population due to severe longterm sequelae. Radiation is considered in the treatment of adult patients with CPC. 5 With incomplete resection of CPC, second surgery may be beneficial. 4 One study of patients with CPC who had surgery was divided into subgroups of patients with completely resected tumors and incompletely resected tumors. 4 In those with incompletely resected tumors, 22.6% had a second surgery, and these patients had an increased 2-year survival of 69% compared with a survival of 30% for patients without second surgery. 4 CONCLUSION Choroid plexus carcinoma is an uncommon tumor that usually occurs in the lateral and fourth ventricles. It is associated with a poor prognosis. While the median age of occurrence is 26 to 32 months, this neoplasm should be considered in the differential diagnoses of a papillary intraventricular neoplasm, especially in children and less commonly in adults. Choroid plexus carcinoma is a WHO grade III tumor which is distinguished histologically from CPP based on increased nuclear to cytoplasmic ratios, increased mitotic figures, nuclear pleomorphism, the presence of necrosis, and distortion or blurring of the papillary structure of CPP by sheets of cells in the malignant counterpart. Immunohistochemical stains, while not entirely specific, can be useful in the diagnosis of CPC. Molecular studies including microarray analysis of CPC have identified other markers that may be useful in its diagnosis. CPC has been associated with Li-Fraumeni syndrome, and five additional families with children with CPC and the TP53 mutation were recently identified, suggesting that the presence of CPC in a family could be used as an indicator of a germline TP53 mutation. The current accepted treatment for CPC is surgical excision with controversial use of adjuvant chemotherapy. Although difficult due to the excessive vascularity of the tumor, gross total resection is the surgical goal, since this is associated with the most favorable prognosis. We would like to thank Barbara K. Pawely, MD, of the Department of Radiology at Kosair Children s Hospital for providing the neuroimaging studies. References 1. Paulus W, Brandner S. Choroid plexus tumours. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC Press; 2007: Arch Pathol Lab Med Vol 132, August 2008 Choroid Plexus Carcinoma Gopal et al 1353
5 2. Hasselblatt M, Bohm C, Tatenhorst L, et al. Identification of novel diagnostic markers for choroid plexus tumors, a microarray-based approach. Am J Surg Pathol. 2006;30: Chow E, Reardon DA, Shah AB, et al. Pediatric choroid plexus neoplasms. Int J Radiat Oncol Biol Phys. 1999;44: Wrede B, Liu P, Ater J, Wolff JEA. Second surgery and the prognosis of choroid plexus carcinoma-results of a meta-analysis of individual cases. Anticancer Res. 2005;25: Wolff JEA, Sajedi M, Brant R, Coppes M, Egeler RM. Choroid plexus tumors. Br J Cancer. 2002;87: Rickert CH, Paulus W. Tumors of the choroid plexus. Microsc Res Tech. 2001;52: Kimura M, Takayasu M, Suzuki Y, et al. Primary choroid plexus papilloma located in the suprasellar region: case report. Neurosurgery. 1992;31: Carter A, Price D, Tucci K, Lewis G, Mewborne J, Singh H. Choroid plexus carcinoma presenting as an intraparenchymal mass. J Neurosurg. 2001;95: Jeibmann A, Hasselblatt M, Gerss J, et al. Prognostic implications of atypical histologic features in choroid plexus papilloma. J Neuropathol Exp Neurol. 2006; 65: Ironside J, Moss T, Louis D, Lowe J, Weller R. Ependymal and choroid plexus tumors. In: Diagnostic Pathology of Nervous System Tumors. 1st ed. London, United Kingdom: Elsevier Science Limited; 2002: Centeno B, Louis D, Kupsky W, Preffer F, Sobel R. The AgNOR technique, PCNA immunohistochemistry, and DNA ploidy in the evaluation of choroid plexus biopsy specimens. Am J Clin Pathol. 1993;100: Adesina AM. Intraoperative consultation in the diagnosis of pediatric brain tumors. Arch Pathol Lab Med. 2005;129: Singh A, Vermani S, Sharma S, Chand K. Papillary meningioma: a rare but distinct variant of malignant meningioma. Diagn Pathol. 2007;2: Al-Anazi A, Shannon P, Guha A. Solitary metastasis to the choroid plexus. J Neurosurg. 2000;92: Kohno M. Solitary metastasis to the choroid plexus of the lateral ventricle: report of three cases and a review of the literature. J Neurooncol. 1996;27: Coffin C, Wick M, Braun J, et al. Choroid plexus neoplasms: clinicopathologic and immunohistochemical studies. Am J Surg Pathol. 1986;10: Paulus W, Brandner S. Synaptophysin in choroid plexus epithelial cells: no useful aid in differential diagnosis [letter]. J Neuropathol Exp Neurol. 1999;58: Paulus W, Janisch W. Clinicopathologic correlations in epithelial choroid plexus neoplasms: a study of 52 cases. Acta Neuropathol. 1990;80: Judkins A, Burger P, Hamilton R, et al. INI1 expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol. 2005;64: Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. New Engl J Med. 2002;346: Carlotti C, Salhia B, Weitzman S, et al. Evaluation of a proliferative index and cell cycle protein expression in choroid plexus tumors in children. Acta Neuropathol. 2002;103: Krutilkova V, Trkova M, Fleitz J. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer. 2005;41: Kamaly-Asi ID, Shams N, Taylor MD. Genetics of choroid plexus tumors. Neurosurg Focus. 2006;20: Rickert C, Wiestler O, Paulus W. Chromosomal imbalances in choroid plexus tumors. Am J Pathol. 2002;160: Dickens D, Dothage J, Heideman R, Ballard E, Jubinsky P. Successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome. J Pediatr Hematol Oncol. 2005;27: Packer R, Perilongo G, Johnson D, et al. Choroid plexus carcinoma of childhood. Cancer. 1992;69: Pierga J, Kalifa C, Terrier-Lacombe MJ, et al. Carcinoma of the choroid plexus: a pediatric experience. Med Pediatr Oncol. 1993;21: St. Clair S, Humphreys R, Pillay P, et al. Current management of choroid plexus carcinoma in children. Pediatr Neurosurg. 1991;17: Berger C, Thiesse P, Lelouch-Tubiana A, et al. Choroid plexus carcinomas in childhood: clinical features and prognostic factors. Neurosurgery. 1998;42: Chow E, Jenkins JJ, Burger PC, et al. Malignant evolution of choroid plexus papilloma. Pediatr Neurosurg. 1999;31: Arch Pathol Lab Med Vol 132, August 2008 Choroid Plexus Carcinoma Gopal et al
Something Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
More informationCase Report. Central Neurocytoma. Fotis Souslian, MD; Dino Terzic, MD; Ramachandra Tummala, MD. Department of Neurosurgery, University of Minnesota
1 Case Report Central Neurocytoma Fotis, MD; Dino Terzic, MD; Ramachandra Tummala, MD Department of Neurosurgery, University of Minnesota Case This is a previously healthy 20 year old female, with 3 months
More informationGlioblastoma (cancer affecting the brain) A guide for journalists on glioblastoma and its treatment
Glioblastoma (cancer affecting the brain) A guide for journalists on glioblastoma and its treatment Section 1 Glioblastoma Section 2 Epidemiology and prognosis Section 3 Treatment Contents Contents 2 3
More informationUpdate on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationPRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
More informationMAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER
Renal tumours WHO 4 MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER Molecular differential pathology of renal cell tumours G. KOVACS A CLASSIFICATION BASED ON UNDERSTANDING THE GENETIC
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationATLAS OF HEAD AND NECK PATHOLOGY THYROID PAPILLARY CARCINOMA
Papillary carcinoma is the most common of thyroid malignancies and occurs in all age groups but particularly in women under 45 years of age. There is a high rate of cervical metastatic disease and yet
More informationSeattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
More informationBrain Cancer. This reference summary will help you understand how brain tumors are diagnosed and what options are available to treat them.
Brain Cancer Introduction Brain tumors are not rare. Thousands of people are diagnosed every year with tumors of the brain and the rest of the nervous system. The diagnosis and treatment of brain tumors
More informationRenal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationDiagnostic Challenge. Department of Pathology,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
More informationMedullary Renal Cell Carcinoma Case Report
Bahrain Medical Bulletin, Vol. 27, No. 4, December 2005 Medullary Renal Cell Carcinoma Case Report Mohammed Abdulla Al-Tantawi MBBCH, CABS* Abdul Amir Issa MBBCH, CABS*** Mohammed Abdulla MBBCH, CABS**
More informationToday s Topics. Tumors of the Peritoneum in Women
Today s Topics Tumors of the Peritoneum in Women Charles Zaloudek, M.D. Department of Pathology 505 Parnassus Ave., M563 University of California, San Francisco San Francisco, CA USA charles.zaloudek@ucsf.edu
More informationPractical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationThe evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
More informationHigh-grade glioma in a patient with breast cancer
Asian Journal of Surgery (2014) 37, 162e166 Available online at www.sciencedirect.com journal homepage: www.e-asianjournalsurgery.com CASE REPORT High-grade glioma in a patient with breast cancer Che-Chao
More informationDESMOPLASTIC SMALL ROUND CELL TUMOR: A RARE PATHOLOGY PUZZLE
DESMOPLASTIC SMALL ROUND CELL TUMOR: A RARE PATHOLOGY PUZZLE Ryan Granger University of Rhode Island Cytotechnology program May 2, 2015 ASCT Annual Meeting Nashville, Tennessee DESMOPLASTIC SMALL ROUND
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationHistopathology of Colorectal Cancer after Neoadjuvant Chemoradiation Therapy
The Open Pathology Journal, 2009, 3, 91-98 91 Open Access Histopathology of Colorectal Cancer after Neoadjuvant Chemoradiation Therapy Maura O Neil * and Ivan Damjanov Department of Pathology and Laboratory
More informationIntroduction to Pathology and Diagnostic Medicine
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Introduction to Pathology and Diagnostic Medicine Spring 2003 What is pathology?
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
More informationHistologic Subtypes of Renal Cell Carcinoma
Histologic Subtypes of Renal Cell Carcinoma M. Scott Lucia, MD Associate Professor Chief of Genitourinary and Renal Pathology Director, Prostate Diagnostic Laboratory Dept. of Pathology University of Colorado
More informationDiagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationA 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
More informationOutline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Ependymoma
AMERICAN BRAIN TUMOR ASSOCIATION Ependymoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization
More informationJ of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063
PERITONEAL MALIGNANT MESOTHELIOMA: A RARE S. R. Dhamotharan 1, S. Shanthi Nirmala 2, F. Celine Foustina Mary 3, M. Arul Raj Kumar 4, R. Vinothprabhu 5 HOW TO CITE THIS ARTICLE: S. R. Dhamotharan, S. Shanthi
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationHKCPath Anatomical Pathology Peer Review and Scores : PDF version for download
AP2003R1 http://hkcpath.org. Correspondence: pkhui@ha.org.hk 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma from
More informationMetastatic renal cell carcinoma to the left maxillary sinus
Case Report Metastatic renal cell carcinoma to the left maxillary sinus Y.-F. He 1, J. Chen 1, W.-Q. Xu 2, C.-S. Ji 1, J.-P. Du 1, H.-Q. Luo 1 and B. Hu 1 1 Department of Medical Oncology, The Provincial
More informationTHYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
More informationRenal Tumors with Eosinophilic Cytoplasm: 2013 Classification. Jesse K. McKenney, MD Associate Head, Surgical Pathology
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification Jesse K. McKenney, MD Associate Head, Surgical Pathology Renal Epithelial Neoplasia History 1981: WHO Classification of Renal Neoplasms 1.
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationMale. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
More informationAtypical uterine leiomyoma: a case report and review of the literature
Manxhuka-Kerliu et al. Journal of Medical Case Reports (2016) 10:22 DOI 10.1186/s13256-016-0800-3 CASE REPORT Open Access Atypical uterine leiomyoma: a case report and review of the literature Suzana Manxhuka-Kerliu
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationThe develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
More informationKIDNEY CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATION / TFE3 (ASPL-TFE3) GENE FUSION
Case Report International Braz J Urol Official Journal of the Brazilian Society of Urology KIDNEY CA AND Xp11.2 TRANSLOCATION Vol. 31 (3): 251-255, May - June, 2005 KIDNEY CARCINOMA ASSOCIATED WITH XP11.2
More informationThe Brain and Spine CenTer
The Br ain and Spine Center Choosing the right treatment partner is important for patients facing tumors involving the brain, spine or skull base. The Brain and Spine Center at The University of Texas
More informationSEMESTER VI 3 RD YEAR PATHOLOGY KIDNEY TUMORS
SEMESTER VI 3 RD YEAR PATHOLOGY KIDNEY TUMORS LEARNING OBJECTIVES At the end of the lecture, students should be able to: Know the pathology of renal tumors. RENAL TUMORS RENAL PAPILLARY ADENOMA Common
More informationCASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY
CASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY CASE HISTORY 52Y MALE RIGHT RADICAL NEPHERECTOMY Case of right renal mass with IVC thrombus. History of surgery and RT for right occipital
More informationCarcinosarcoma of the Ovary
Carcinosarcoma of the Ovary A Rare Finding Presented By: Kathryn Kiely Anisa I. Kanbour School of Cytotechnology of the University of Pittsburgh Medical Center Pittsburgh, PA Patient History 55 year old
More informationPrimary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low
More informationHistopathology of Major Salivary Gland Neoplasms
Histopathology of Major Salivary Gland Neoplasms Sam J. Cunningham, MD, PhD Faculty Advisor: Shawn D. Newlands, MD, PhD Faculty Advisor: David C. Teller, MD The University of Texas Medical Branch, Department
More informationNational Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s National Cancer Institute
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationPATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationRENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE
RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER Molecular differential pathology of renal cell tumours
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationHistopathology and prognosis in renal cancer
Histopathology and prognosis in renal cancer Granular cell Granular cell Granular cell Granular cell Clear cell Chromophobe cell Papillary type 2 Luca Mazzucchelli Istituto cantonale di patologia, Locarno
More informationPRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including anaplastic, gliosarcoma and glioblastoma multiforme)
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including
More informationYOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
More informationPediatric Brain Tumors: Lecture 1 Posterior Fossa
Pediatric Brain Tumors: Lecture 1 Posterior Fossa Jerome M. Volk III, PGY 6 LSU March 28 & 29, 2014 Epidemiology Compromise ~20% of all pediatric cancers Incidence of 2.4 3.5/100,000 children Roughly 3,000
More informationThe Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.
Where does Molecular Analysis of FNA Specimens fit into the evaluation of thyroid nodules? The Role of Genetic Testing in the Evaluation of Thyroid Nodules Ultrasound TSH Risk factors Jill E. Langer, MD
More informationIntraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas
International Urology and Nephrology 28 (1), pp. 73-77 (1996) Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas $. O. OZDAMAR,*
More informationLung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
More informationClassificazioni citologiche: verso uno schema internazionale unificato?
Cytology and molecular biology for thyroid nodules diagnos6c categories to clinical ac6ons From Classificazioni citologiche: verso uno schema internazionale unificato? A. Crescenzi Diagnostic categories
More informationThursday, November 3, 2005
Thursday, November 3, 2005 8:30-10:30 a. m. Gastric Tumors, Session 1 Chairman: P. Ruszniewski, Clichy, France 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders: G. Rindi, Parma,
More informationPROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationhttp://www.springer.com/3-540-22006-2
http://www.springer.com/3-540-22006-2 1 Molecular Pathology Laboratory of the Future Christopher A. Moskaluk 1.1 The Past The integration of laboratory analysis with human medicine has traditionally been
More informationCase of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
More informationCytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationBrain Tumor Treatment
Scan for mobile link. Brain Tumor Treatment Brain Tumors Overview A brain tumor is a group of abnormal cells that grows in or around the brain. Tumors can directly destroy healthy brain cells. They can
More informationInformation Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports
Information Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports W. Scott Campbell, Ph.D., MBA James R. Campbell, MD Acknowledgements Steven H. Hinrichs, MD Chairman
More informationCHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
More informationThe Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationRenal Cell Carcinoma Associated with Xp11.2 Translocation: Clinicopathologic and Immunohistochemical Findings of 4 Cases
The Korean Journal of Pathology 2005; 39: 406-11 Renal Cell Carcinoma Associated with Xp11.2 Translocation: Clinicopathologic and Immunohistochemical Findings of 4 Cases Sanghui Park Ji-Eun Kwon Yeon-Lim
More informationRenal Pathology Update. Sundus Hussein MD, FRCPC
Renal Pathology Update Sundus Hussein MD, FRCPC Case History A 45 year old male with incidentally discovered a 3.5 x 3.9 x 2.7 cm renal mass Handling partial nephrectomy Handling partial nephrectomy
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationCT and MRI features of the Pathologic Subtypes of Papillary Renal Cell Carcinoma. Melissa Price, MD Aoife Kilcoyne, MD Mukesh G.
CT and MRI features of the Pathologic Subtypes of Papillary Renal Cell Carcinoma Melissa Price, MD Aoife Kilcoyne, MD Mukesh G. Harisinghani, MD Disclosures Neither I nor my immediate family members have
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationTubulocystic Carcinoma of the Kidney, a Rare Distinct Entity
Tubulocystic Carcinoma of the Kidney, a Rare Distinct Entity 2 Shreenath Bishu, Laurie J. Eisengart and Ximing J. Yang * Department of Pathology, Northwestern University, Feinberg School of Medicine, Feinberg,
More informationImmunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationInteresting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
More informationASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3
ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,
More informationNicole Kounalakis, MD
Breast Disease: Diagnosis and Management Nicole Kounalakis, MD Assistant Professor of Surgery Goal of Breast Evaluation The goal of breast evaluation is to classify findings as: normal physiologic variations
More informationChallenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014 Prof. Dr. Chris Verslype, Leuven Prof. Dr. Aurel Perren, Bern Menue Challenges: 1. Gastric NET 2. Appendiceal NET 3. Rectal NET SEER,
More informationLIVER TUMORS PROFF. S.FLORET
LIVER TUMORS PROFF. S.FLORET NEOPLASM OF LIVER PRIMARY 1)BENIGN 2)MALIGNANT METASTATIC/SECONDARY LIVER Primary Liver Cancer the Second Killer among tumors high morbidity and mortality(20.40/100,000) etiology
More informationTechnological Innovation: High Field Open Magnetic Resonance Spectroscopy
Technological Innovation: High Field Open Magnetic Resonance Spectroscopy Student Investigator: Thomas R. Pace UVM COM Class of 2012 Faculty Mentor: Christopher Filippi Department of Radiology Fletcher
More informationSternotomy and removal of the tumor
Sternotomy and removal of the tumor All thymomas originate from epithelial thymic cells 4% of them consist of a pure population of epithelial cells Most have mixed populations of lymphoid cells to a
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationMolecular Diagnostics in Thyroid Cancer
Disclosure Nothing to disclose Jonathan George, MD, MPH Assistant Professor Head and Neck Oncologic & Endocrine Surgery Molecular Diagnostics in Thyroid Cancer Current Practices & Future Trends UCSF Medical
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationCorporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid
Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid
More informationBRAF in the diagnostic evaluation of thyroid nodules
Symposium 13 Molecular markers in thyroid cancer: current role in clinical practice BRAF in the diagnostic evaluation of thyroid nodules Laura Fugazzola University of Milan, Italy Papillary carcinoma BRAF
More informationTitle: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma
Author's response to reviews Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Authors: Tanner L Bartholow (bartholow.tanner@medstudent.pitt.edu) Uma R Chandran (chandranur@msx.upmc.edu)
More information